Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
Saved in:
| Title: | Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. |
|---|---|
| Authors: | Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA., Smith SD; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Roschewski MJ; National Cancer Institute, Bethesda, MD, USA., O'Brien SM; Chao Family Comprehensive Cancer Center, University of California-Irvine, Irvine, CA, USA., Sharman JP; Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, OR, USA., Melear JM; Texas Oncology, Austin, TX, USA., Patel P; AstraZeneca, South San Francisco, CA, USA., Calvo R; AstraZeneca, Gaithersburg, MD, USA., Yang H; AstraZeneca, South San Francisco, CA, USA., Spurgeon SE; Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USA. |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2022 Jul; Vol. 63 (7), pp. 1728-1732. Date of Electronic Publication: 2022 Feb 24. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1029-2403 |
|---|---|
| DOI: | 10.1080/10428194.2022.2043301 |
